GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pure Biologics PUR.WA · PLN

Health Care · GPW · 🇵🇱 Poland

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Pure Biologics

Its shares trade on GPW under the ticker PUR.WA. It has been listed since 11 December 2018. In the fiscal year to 31 December 2023, it reported revenue of PLN 95,000 and a net loss of PLN 35.7m. At that date it held total assets of PLN 22.7m and shareholders' equity of PLN 1.9m.

Pure Biologics SA is a biopharmaceutical company, which engages in the research and development of innovative biological medicines and medical devices for use therapeutic and diagnostic tests. The company is headquartered in Wroclaw, Woj. Dolnoslaskie. The company went IPO on 2018-12-11. The firm was founded in August 2010 and is located in Wroclaw, Poland.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
11 Dec 2018
Employees
53

Leadership

Pay as last reported

  • Mr. Filip JelenChairman of the Management Board
  • Mr. Miroslaw CiucmanMember of the Supervisory Board
  • Dr. Mariusz CzekalaMember of the Supervisory Board
  • Mr. Andrzej Mieczyslaw KierzkowskiMember of the Supervisory Board
  • Ms. Katarzyna SuchoszekMember of the Supervisory Board

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Pure Biologics SA employs 53 full-time employees in Wroclaw, Poland.
  • The company's focus on biopharmaceutical R&D aligns with Health Care sector growth.
  • Founded in August 2010, Pure Biologics SA has a 14-year operational history.

Weaknesses

  • The company's IPO on 11 December 2018 may indicate limited market capitalization.
  • Wroclaw, Poland, is not a major biotech hub compared to global centers.
  • Pure Biologics SA has no mentioned partnerships with large pharmaceutical firms.

Opportunities

  • Poland's growing Health Care sector offers expansion potential for Pure Biologics SA.
  • Biotechnology industry growth in Eastern Europe supports Pure Biologics SA's market entry.
  • The company can leverage its 14-year experience to develop new therapeutic products.

Threats

  • Competition from established biotech firms in the Health Care sector.
  • Regulatory challenges in Poland's biopharmaceutical market may increase costs.
  • The limited employee count of 53 may hinder rapid scaling efforts.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.